<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135585</url>
  </required_header>
  <id_info>
    <org_study_id>2021-059</org_study_id>
    <secondary_id>2021-A01949-32</secondary_id>
    <nct_id>NCT05135585</nct_id>
  </id_info>
  <brief_title>Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population</brief_title>
  <acronym>COVCAL</acronym>
  <official_title>Evaluation of the Post-vaccination Immune Response to COVID-19 in the New Caledonian Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Spécialisé de Nouvelle-Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Direction de l'Action Sanitaire et Sociale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Territorial de Nouvelle-Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agence sanitaire et sociale de la Nouvelle Calédonie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 pandemic caused by SARS-CoV-2 since December 2019 has caused more than 210&#xD;
      million cases worldwide as of September 1, 2021. New Caledonia (NC) is an ultramarine French&#xD;
      territory in the South Pacific so far relatively spared by this pandemic thanks to the&#xD;
      establishment of a health lock. The vaccination campaign started locally on 20/01/2021 with&#xD;
      the exclusive use of Pfizer's COMIRNATY mRNA vaccine. Vaccination is now offered to anyone&#xD;
      over the age of 12. Vaccination against COVID-19 will be mandatory in New Caledonia as of&#xD;
      October 31, 2021 for certain exposed populations and for the entire adult population as of&#xD;
      December 31, 2021.&#xD;
&#xD;
      Clinical trials of COVID-19 vaccines, including those of mRNA vaccines, have taken care to&#xD;
      maintain ethnic diversity within their samples. Efficacy studies have not shown a significant&#xD;
      difference in the efficacy of Pfizer COMIRNATY vaccine in white, black American, or Hispanic&#xD;
      populations. The response of non-European non-Asian Oceanian populations to Pfizer COMIRNATY&#xD;
      vaccination has not been specifically studied at this time. According to the 2019 census in&#xD;
      New Caledonia, 41.2% of the population identified themselves as Kanak (Melanesian), 24% as&#xD;
      European, 8.3% as Wallisian-Futunian (Polynesian), 11% as mestizo, and 8% as belonging to&#xD;
      other communities including Tahitian (Polynesian), Indonesian, Ni-Vanuatu (Melanesian), and&#xD;
      Vietnamese communities (8). Some recent data are in favor of a significant variability of&#xD;
      susceptibility to pathogens in Oceanian populations, stemming from a genetic inheritance from&#xD;
      Neanderthal man and his cousin Denisova man. In a context of vaccine hesitancy, it is&#xD;
      therefore important to ensure that the immune response of the New Caledonian population&#xD;
      (Melanesian, Polynesian, European or other communities) to vaccination against COVID-19 is&#xD;
      similar to that of populations studied in large clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational equivalence study with prospective data collection. Vaccinated subjects to be&#xD;
      included will be identified in the vaccination centers in the Southern Province during the&#xD;
      injection of the second dose.&#xD;
&#xD;
      Information and consent collection. Completion of a questionnaire and collection of 4 mL of&#xD;
      blood on a dry tube at M1 and M6 months.&#xD;
&#xD;
      Testing for the presence of anti-SARS-CoV-2 antibodies by ELISA (anti-Spike and&#xD;
      anti-Nucleoprotein).&#xD;
&#xD;
      Return of the results of the serological analyses to the participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement by ELISA tests of the presence of antibodies at 1 month after the second dose of Pfizer COMIRNATY vaccine in the New Caledonian population</measure>
    <time_frame>6 months</time_frame>
    <description>To assess in a standardized manner the humoral immune response to COVID-19 vaccination at 1 month after the second dose in vaccinated individuals of Polynesian, Melanesian, European and other communities in New Caledonia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement by ELISA of the presence of antibodies at 6 months after the second dose of Pfizer COMIRNATY vaccine in the New Caledonian population</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate and compare in a standardized manner the humoral immune response to COVID-19 vaccinationat 6 months after the second dose of Pfizer COMIRNATY vaccine in vaccinated individuals of Polynesian, Melanesian, European and other communities in New Caledonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralization analysis of the neutralizing capacity against different circulating SARS-CoV-2 variants of antibodies secreted at 1 and 6 months after the second dose of Pfizer COMIRNATY vaccine in the New Caledonian population</measure>
    <time_frame>1 year</time_frame>
    <description>To study the functionality (neutralizing capacity) of antibodies secreted in response to COVID-19 vaccination by individuals of Melanesian, Polynesian, European and other community origin at 1 month and 6 months after the second dose of Pfizer COMIRNATY vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-hoc analysis of anti-Spike and anti-Nucleoprotein ELISA results at 1 month by age stratification (group over 70 years and control group 20-59 years)</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate and compare in a standardized way the humoral immune response to the COVID-19 vaccination at 1 month after the second dose of Pfizer COMIRNATY vaccine in subjects aged over 70 years and a control group in the New Caledonian population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>SARS-CoV-2 Acute Respiratory Disease</condition>
  <arm_group>
    <arm_group_label>Adults vaccinated with a complete COVID-19 vaccine regimen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adults of Melanesian, Polynesian, European, and other communities vaccinated with a complete COVID-19 vaccine regimen, residing in New Caledonia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood sample collection at 1 month and 6 months after vaccination</description>
    <arm_group_label>Adults vaccinated with a complete COVID-19 vaccine regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>data collection (health data, vaccination data, etc.)</description>
    <arm_group_label>Adults vaccinated with a complete COVID-19 vaccine regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults from Melanesian, Polynesian, European or other community origin&#xD;
&#xD;
          -  Adults vaccinated with 2 doses of Pfizer COMIRNATY vaccine, administered between 3 and&#xD;
             12 weeks apart&#xD;
&#xD;
          -  Adults planning to be present in the territory and to be available on both sampling&#xD;
             dates (1 and 6 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Persons who received the second dose of vaccine more than 12 weeks after the first&#xD;
             dose&#xD;
&#xD;
          -  Persons vaccinated against COVID-19 with a vaccine other than Pfizer COMIRNATY&#xD;
&#xD;
          -  Women who report being pregnant or breastfeeding (where the immune response may be&#xD;
             altered)&#xD;
&#xD;
          -  Immunocompromised persons (immunosuppressive treatment, immunomodulator, HIV positive,&#xD;
             splenectomy, long term corticosteroid therapy, autoimmune diseases such as rheumatoid&#xD;
             arthritis, lupus, spondyloarthritis, etc.)&#xD;
&#xD;
          -  People who are not intellectually capable of answering the questionnaire&#xD;
&#xD;
          -  Persons under guardianship, curatorship or any other legal incapacity&#xD;
&#xD;
          -  Persons with documented Covid-19 infection (known positive SARS-CoV-2 serology prior&#xD;
             to inclusion, positive PCR or antigen test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myrielle Dupont-Rouzeyrol, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur de Nouvelle-Calédonie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valérie Albert-Dunais, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Spécialisé de Nouvelle-Calédonie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myrielle Dupont-Rouzeyrol, PhD</last_name>
    <phone>+687 27 75 30</phone>
    <email>mdupont@pasteur.nc</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Inizan, PhD</last_name>
    <phone>+687 27 26 66</phone>
    <email>cinizan@pasteur.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Territorial de Nouvelle-Calédonie</name>
      <address>
        <city>Dumbéa Sur Mer</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre-Henri Moury, MD</last_name>
      <phone>+687 208000</phone>
      <email>pierre-henri.moury@cht.nc</email>
    </contact>
    <investigator>
      <last_name>Pierre-Henry Moury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier spécialisé de Nouvelle-Calédonie</name>
      <address>
        <city>Nouméa</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <contact>
      <last_name>Valérie Albert-Dunais, MD</last_name>
      <phone>+687 24 61 14</phone>
      <email>v.albert-dunais@chs.nc</email>
    </contact>
    <investigator>
      <last_name>Valérie Albert-Dunais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaccination centers</name>
      <address>
        <city>Province Sud</city>
        <country>New Caledonia</country>
      </address>
    </facility>
    <contact>
      <last_name>Georges Medevielle, MD</last_name>
      <phone>+687 204400</phone>
      <email>georges.medevielle@province-sud.nc</email>
    </contact>
    <contact_backup>
      <last_name>Marc Jouan, MD</last_name>
      <phone>+687 27 02 80</phone>
      <email>mjouan@pasteur.nc</email>
    </contact_backup>
    <investigator>
      <last_name>Georges Medevielle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Jouan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Caledonia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune Response</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Pacific</keyword>
  <keyword>Population of New Caledonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

